| Factor | Wegovy | Zepbound |
|---|---|---|
| Molecule | Semaglutide | Tirzepatide |
| Mechanism | GLP 1 agonist | Dual GIP + GLP 1 agonist |
| Manufacturer | Novo Nordisk | Eli Lilly |
| FDA approval (weight) | June 2021 | November 2023 |
| Trial weight loss (avg) | 14.9% at 68 weeks (STEP 1) | 20.9% at 72 weeks (SURMOUNT 1) |
| Real-world weight loss | 9.1% at 12 months (Truveta) | 12.4% at 12 months (Truveta) |
| Dose escalation steps | 0.25 to 2.4 mg (5 steps over 16 weeks) | 2.5 to 15 mg (6 steps over 20 weeks) |
| Nausea rate | 44.2% | 39.0% |
| Discontinuation rate | 7.0% | 6.2% |
| Monthly cost (no insurance) | $1,349 | $1,059 |
| Eli Lilly Direct (cash) | N/A | $349-$549/mo for vials |
In the SURMOUNT 5 trial published in 2024, Zepbound was compared directly against Wegovy in the same patient population. Zepbound showed 47 percent more weight loss than Wegovy at 72 weeks. This is the cleanest head-to-head comparison available.
However, real-world data narrows the gap. Truveta's 2024 cohort analysis showed 12.4 percent at 12 months for Zepbound vs 9.1 percent for Wegovy. The 3.3 percentage point real-world gap is smaller than the trial gap because real-world adherence and dose escalation are limited for both medications.
Despite Zepbound's stronger effect, side effect rates are similar or slightly lower than Wegovy in the FDA prescribing information data. This is a counterintuitive finding because more potent medications typically have more side effects. The dual GIP + GLP 1 mechanism may produce smoother appetite suppression and less aggressive GI side effects.
Practically, most patients tolerate both medications similarly in the first 4 to 8 weeks. Beyond that, individual response varies significantly.
Eli Lilly launched a direct-to-consumer program for Zepbound in 2024, offering vials at $349 to $549 per month depending on dose. This is significantly cheaper than Wegovy's list price of $1,349 per month or even with most discount cards. For cash payers, Zepbound is now the better choice on cost alone.
For insured patients, coverage varies. Wegovy has been covered longer and has broader formulary acceptance. Zepbound coverage is growing in 2026.
Choose Wegovy if:
Choose Zepbound if:
Food guidance is similar for both medications. The services below have high protein options that match the eating patterns most users need on either drug.
See our GLP 1 meal delivery hub for the full ranking.
For pure weight loss, Zepbound shows larger average outcomes (20.9 percent vs 14.9 percent at maximum doses). For cost without insurance, Zepbound is also cheaper through Eli Lilly Direct. Wegovy has the longer real-world track record and broader insurance coverage.
Yes. Zepbound (tirzepatide) is a dual GIP and GLP 1 receptor agonist while Wegovy (semaglutide) only acts on GLP 1. Head to head SURMOUNT 5 trial data shows Zepbound produces 47 percent more weight loss than Wegovy.
Surprisingly, no. Side effect rates including nausea, vomiting, and diarrhea are similar or slightly lower on Zepbound vs Wegovy per FDA prescribing data. The dual mechanism may produce smoother appetite suppression.
Yes, with prescriber guidance. The switch is common in 2026. Most clinicians wait 1 to 2 weeks after the last Wegovy injection, then start Zepbound at the 2.5 mg starter dose to allow appetite suppression to reset.
Zepbound is cheaper in 2026. Eli Lilly Direct offers Zepbound vials at $349 to $549 per month vs Wegovy's list price of $1,349 per month. For insured patients, coverage varies.
Answer 5 quick questions. We'll match you to the top 3 from 24 services we track.